Roche profit rises 25 per cent

Basel-based pharmaceuticals group Roche has reported a profit of SFr11.4 billion ($10.44 billion) for 2007, beating analysts' expectations.

This content was published on January 30, 2008

Profit was up 25 per cent on the preceding year. Turnover also grew ten per cent to SFr46.1 billion – the seventh consecutive year of double-digit growth.

The better turnover came despite a 19 per cent drop in sales of bird flu drug Tamiflu, as most pandemic stockpiling orders were completed in the second half.

Analysts say the company's world-leading portfolio of cancer drugs, including Avastin and Herceptin, helped it escape many of the problems that beset competitors last year.

The Roche result surpasses that of Basel rival Novartis which recorded sales last year of SFr43.8 billion.

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Weekly top stories

Keep up to date with the best stories from SWI on a range of topics, straight into your mailbox.


The SBC Privacy Policy provides additional information on how your data is processed.